76 results about "Glucuronates" patented technology

The invention discloses a carboxylic ester of fucosylated glycosaminoglycan (CEFG) with anticoagulation activity, a pharmaceutically acceptable salt thereof, a preparation method of the CEFG and the pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the CEFG or the salt thereof, and application of the pharmaceutical composition in preparation of anticoagulants. The monosaccharides for preparing the CEFG comprise D-glucuronic acid or D-glucuronate (D-GlcU), D-2-deoxy-2-acetyl galactosamine sulfate (D-GalNAcS) and L-fucose sulfate (L-FucS), wherein the molar ratio of D-GlcU to D-GalNAc to L-Fuc to -OSO3<-> is 1:(1+ / -0.3):(1+ / -0.3):(3.5+ / -0.5); the esterification degree of the D-GlcU is not lower than 20%; and the weight average molecular weight of the CEFG is 3000-20000 Da. The glycosylated chondroitin sulfate esterification derivative has strong anticoagulation activity, and can be applied in preparation of drugs for preventing and / or treating thrombotic diseases.

The present invention relates to the field of cosmetic and dermopharmaceutical compositions. It concerns oligomer compounds of D-glucuronic acid or D-glucuronate with a β (1-4) sequence (or oligoglucuronans) containing a degree of acetylation specifically between 8.7±0.5 and 9.2±0.5% by weight of O—CO—CH3 group compared to the weight of glucuronic acid and with a degree of polymerisation (DP) of 18−19±2. The oligomer compounds according to the present invention are intended to stimulate the elasticity of the dermis and epidermis although they also act to increase derma-epidermal cohesion in order to combat skin ageing, lines, wrinkles, visible and / or tactile skin discontinuities, loss of firmness, elasticity and tone and to combat skin tissue deformability. The invention also concerns a cosmetic composition containing at least one compound as recited according to the present invention.

The invention discloses a synthesis method and an intermediate compound of morphine-6-Beta-D-glucuronide. The synthesis method comprises the following steps: (1) carrying out a reaction on 3-acetyl morphine and acyl-protected glucuronate in an organic solvent 1 under the catalysis of lewis acid so as to obtain an intermediate shown as a formula (IV); (2) hydrolyzing the intermediate shown as the formula (IV) with lithium hydroxide and neutralizing the intermediate shown as the formula (IV) with hydrobromic acid in a mixture solvent of C1-C4 alkanol and water; and washing the intermediate with the C1-C4 alkanol and drying, thereby obtaining the intermediate compound of the morphine-6-Beta-D-glucuronide, wherein the definitions of substituent groups in the formula (III) and the formula (IV) are shown in the specification. The synthesis method has the advantages of moderate condition and high yield, and is simple to operate and easy to industrialize.

The invention discloses a methods used for producing glucuronic acid, and a special-purpose engineering bacteria of the method. A first method comprises following steps: inositol is taken as a raw material, under the effect of the engineering bacteria, glucuronic acid is produced; the engineering bacteria is a recombinant bacteria capable of expressing function protein, and is obtained through introduction of functional genes used for coding the function protein into starting bacteria. A second method comprises following steps: inositol is taken as a raw material, under the effect of the function protein, glucuronic acid is produced; the function protein is one selected from (a1), or (a2), or (a3); (a1) the protein is represented by sequence table 3; (a2), the protein is a fusion protein obtained through connecting the N terminal or / and the C terminal of the protein in (a1) with labels; and (a3), the protein is represented by sequence table 7. Great economical benefit is achieved in glucuronic acid production, and high popularization application value is achieved.

The invention relates to the field of drug synthesis and discloses a method for preparing 5,6,4'-trihydroxy flavone-7-0-D-glucuronic acid. The method is characterized by taking 5,6,7,4'-tetrahydroxy flavone as a raw material, adopting a brand-new synthetic route and carrying out three-step reactions including acylation reaction, glycosylation reaction and acid neutralization reaction after alkaline hydrolysis reaction, thus preparing high-purity 5,6,4'-trihydroxy flavone-7-0-D-glucuronic acid. The preparation method has the advantages of short synthetic route, low cost, high reaction yield and easiness in product purification, and is suitable for industrial production of 5,6,4'-trihydroxy flavone-7-0-D-glucuronic acid.

The present invention provides for a crystalline form of trimetrexate either as a glucuronate, acetate, hydrochloride, methanosulfonate or lactate salt, which can be processed galenically as a stable, well-defined solid substance and processes for producing the crystalline forms. Such crystalline forms allow for prolonged stability in storage and for oral and intravenous administration of the drug.

The invention discloses a ploysulfated chondroitin sulfate, containing glucuronic acid derivant and acetaminogalactose derivant in molecule, the characteristics of the invention comprising: the molecular structure comprises 2-0-sulfuric acid- glucuronic acid- (1í·3)-2-N- acetyl group- 2- deoxidation- 4 or 6-0-sulfuric acid galactose, the molecular weight is 1KD-30KD, and the proportion between sulfate radical and carboxylate is 2-4. The invention also discloses a method for preparing the ploysulfated chondroitin sulfate, that is by sulphonating the chondroitin sulfate. The ploysulfated chondroitin sulfate possesses appreciable action of resisting tumour breeding, inhibiting tumour transferring and inhibiting mastocyte pulling-off granule, and etc, the anticoagulating potencyíœ 10IU / mg, and also possesses strong antiphlogistic and analgesic action.

An active largehead atractylodes saccharide complex is produced through water soaking largehead atractylodes rhizome, organic solvent precipitating, water dissolving the precipitate, dialyzing or membrane separating the supernatant liquid, concentration and drying to obtain coarse product, column chromatographic separation of the coarse product to obtain fine largehead atractylodes saccharide compound. The process is simple and high in yield and is suitable for industrial production. The largehead atractylodes saccharide complex contains polysaccharide in 40-60 wt%, alduronic acid in 15-45 wt% and protein in 10-25 wt% and the polysaccharide includes glucose, galactose, mannose, arabinose and rhamnose. The largehead atractylodes saccharide complex has obvious blood sugar reducing effect and no toxic side effect.

The invention relates to a pharmaceutical composition comprising a glucuronate, glucoside, and / or sulfo conjugate of 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one, or such a conjugate of a derivative of 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one, or a physiologically well tolerated salt of such a conjugate.

The invention relates to a method for preparing arabinose, galactose, rhamnose and glucuronic acid. According to the invention, Arabic gum is hydrolyzed under acidic conditions to obtain mixed liquorof arabinose, galactose, rhamnose and glucuronic acid, steps of neutralization, filtration, and concentration are carried out to obtain concentrated liquid, and then steps of decolorization, deionization, and separation are carried out to obtain the following products: (1) an arabinose-rich solution is concentrated and crystallized to obtain crystalline arabinose; (2) a galactose-rich solution isconcentrated and crystallized to obtain crystalline galactose; (3) a mixed sugar solution rich in galactose and rhamnose is mixed with the crystalline mother liquor of galactose, and then is subjectedto chromatographic separation to obtain a solution rich in rhamnose, then the solution is concentrated and crystallized to obtain crystalline rhamnose; and (4) a solution rich in glucuronic acid is subjected to ion removal, and then is concentrated and crystallized to obtain the crystalline glucuronic acid.

The invention discloses a substrate for detecting beta-D-glucuronidase. The substrate is specifically thymolphthalein-alpha-D-glucuronic acid. A preparation method comprises the following steps: preparing thymolphthalein-alpha-D-methyl glucuronate through reaction of thymolphthalein and acetyl bromide-alpha-D-methyl gluconate, removing acetyl to obtain the thymolphthalein-alpha-D-methyl gluconate,and then performing hydrolysis reaction, so as to obtain the thymolphthalein-alpha-D-glucuronic acid. As the substrate for detecting the beta-D-glucuronidase, the thymolphthalein-alpha-D-glucuronic acid disclosed by the invention has the advantages of stable property, difficulty in deterioration and sensitivity to development; furthermore, a synthesis process is simple, and the cost can be obviously reduced.

The invention discloses a method for preparing glucuronic acid and lactone thereof by heterogeneous catalytic oxidation of methyl gluoside. The method comprises the following steps: taking a supported palladium / perovskite composite metal oxide as a catalyst, employing dioxygen to perform selective catalytic oxidation for 2-5h on primary hydroxyl of the methyl glucoside, controlling the pH value at 8-11 and the reaction temperature at 60-90 DEG C during the catalytic oxidation, then filtering to separate the catalyst, allowing the filtrate to a hydrolysis reaction for 1-3h with the pH value controlled at 1-3 and the reaction temperature at 60-90 DEG C to obtain the glucuronic acid, and under the condition, the glucuronic acid is partially converted to generate the glucuronic acid lactone. The method has high selectivity and little environmental pollution, helps easily separate the catalyst and meets the development requirements of green chemistry. In the method, the dioxygen is adopted for the selective catalytic oxidation at the normal pressure, which has no special requirements for equipment, ensures simple operation and can realize clean production. A reproducible glucose derivative is taken as a raw material, which ensures a high utilization rate of the raw materials, thus saving resources and lowering the production cost.

The invention relates to the drug synthesis technical field, and in particular, relates to a preparation method of 5,4'-dihydroxy flavone-7-O-D-glucuronic acid. The method comprises the following steps: taking a compound having a structure represented by the formula II, and under an alkaline condition, acylating to obtain a compound having a structure represented by the formula III; taking the compound having the structure represented by the formula III and alpha-bromo triacetoxy methyl glucuronate, and carrying out a glycosylation reaction, to obtain a compound having a structure represented by the formula IV; taking the compound having the structure represented by the formula IV, and hydrolyzing under an acidic condition, to obtain a compound having a structure represented by the formula V; and taking the compound having the structure represented by the formula V, hydrolyzing under an alkaline condition, and thus obtaining the product. The method provided by the invention has the advantages of cheap and easily obtained starting raw materials, less reaction steps, and simple and easily operated process, and is suitable for large-scale industrialized production; and through testing, the purity of the obtained product can reach more than 98%, and the total yield reaches up to 56%.

Sebum production inhibitors containing as an active ingredient a compound of general formula (1) below having a glucuronic acid derivative and a glucosamine derivative in the structure or a pharmacologically acceptable salt thereof

The invention discloses a preparation method of quercetin-3-O-β-D-glucuronic acid. It extracts the traditional Chinese medicine barley as a raw material, and the obtained extract is filtered and concentrated, and the ethanol content is adjusted to 40 ~80%, remove impurities, concentrate the supernatant to dryness, dissolve in methanol-water, reverse phase column chromatography, elute with 20-70% methanol, detect by thin chromatography, recrystallize and depigment the fraction containing the target stream, After drying, the pure quercetin-3-O-β-D-glucuronic acid with a purity greater than 99% can be obtained in batches. The invention has the advantages of less consumption of organic solvent, low toxicity, simple operation, low cost, and easy laboratory small-scale preparation and pilot production.

The object of the present invention is to provide a therapeutic agent for nerve damage caused by spinal cord injury, nerve trauma, etc., which contains low molecular weight sugars as active ingredients. The low molecular weight sugars include at least glucuronic acid and / or N-acetylglucosamine. As constituent sugars or pharmaceutically acceptable salts thereof. Preferably, the nerve damage treatment agent contains low molecular weight hyaluronic acid (further preferably hyaluronic acid disaccharide to hyaluronic acid 2500 sugar, further preferably hyaluronic acid disaccharide to hyaluronic acid 50 sugar, particularly preferably hyaluronic acid tetrasaccharide ) or a pharmaceutically acceptable salt thereof as the active ingredient.

A liposome composition having a protonatable therapeutic agent entrapped in the form of a salt with an glucuronate anion is disclosed. Methods for preparing the composition using an ammonium ion transmembrane gradient having glucuronate as the counterion are also disclsoed. In one embodiment where the protonatable agent is doxorubicin, the method of the invention has comparable loading efficiency, faster release rate, without compromising the therapeutic efficacy compared to loading with an ammonium ion gradient having sulfate as the counterion.

The invention discloses chrysoeriol-7-O-beta-D-butyl glucuronate. The structural formula of the chrysoeriol-7-O-beta-D-butyl glucuronate is shown in the description. The invention also discloses an extraction method of the chrysoeriol-7-O-beta-D-butyl glucuronate and application of the chrysoeriol-7-O-beta-D-butyl glucuronate in preparation of antioxidant drugs, antioxidant cosmetics, hypoglycemic drugs or anti-tumor drugs.

Disclosed are a RGD-peptide-type cationic lipid compound and a preparation method. The compound has a general formula shown in the description. In the formula, X- is one of F-, Cl-, Br-, I-, H2PO4-, HCO3-, NO3-, HSO3-, CH3COO-, gluconate, glucuronate, galactonate, galacturonate, propionate, and methanesulfonate, and R1 is one of a C1-20 alkyl group, octadecenyl, and a cholesterol group. The invention further relates to a composition prepared through mixing and interaction of the compound and a lipid auxiliary agent, and a compound prepared from the composition and a medicine or a genetic material. The compound in the invention is reduced in cytotoxicity and high in transfection efficiency, and can meet the high-efficiency-and-low-toxicity requirement of a carrying medicine including the genetic material and related materials.

The invention discloses a method for quantitative detection of gluconic acids and glucono lactone, and belongs to the technical field of separation and detection. The method mainly adopts an SB-Aq chromatographic column and an amino chromatographic column in a combined manner to qualitatively and quantitatively detect the gluconic acids and the glucono lactone which comprise gluconic acid, glucuronic acid, d-saccharic acid and d-saccharic acid 1,4-lactone. According to the method, firstly, the SB-Aq chromatographic column is adopted to perform direct quantitative analysis on the d-saccharic acid 1,4-lactone in a sample; secondly, the amino chromatographic column is adopted to perform direct quantitative analysis on the glucuronic acid and the d-saccharic acid in the sample; finally, the content of the gluconic acid in the sample is obtained through calculation. The method is simple and convenient in pretreatment, high in sensitivity and capable of determining multiple components, and has important significance of improvement of detection working efficiency, control of kombucha production quality and increase of the functional factor yield.

A novel sweetener extracted from sweet Gynostemma pentaphyllum Makino. has a main structure of ethyl-6-glucuronate-1,4-alpha-D-galactose, and is a natural non-carbohydrate sweetener. A preparation method of the novel sweetener comprises the following steps: selecting sweet Gynostemma pentaphyllum Makino. tea, removing chlorophylls, fats and saponins through an organic solvent, carrying out heat insulation distilled water extraction at 70-100 DEG C for 0.5-2 h, decolorizing obtained extract with H2O2, removing proteins through a Sevage technology, and dialyzing the obtained extract in distilled water through using a dialysis bag with the molecular weight cutoff range of 500-2000 in order to remove most polysaccharide and protein impurities; dialyzing the obtained extract in distilled water through using a dialysis bag with the molecular weight cutoff of 100-500 to remove a small amount of salts and the organic solvent; or directly carrying out water extraction without the organic solvent, and removing impurities through a dialysis technology adopting dialysis bags with different molecular weight cutoffs; and drying the finally obtained extract by using a refrigerating drying machine to obtain a sweetener sample. The sweet Gynostemma pentaphyllum Makino. sweetener has high purity, is a natural novel sweetener, has the sweetness 300-1200 times that of sucrose, and does not insulin metabolism.

The present invention relates to one kind of nanometer antiviral liposome medicine and its preparation process. The nanometer antiviral liposome medicine includes the mixture of alprostadil and Adefovir dipivoxil in the weight ratio of 0.1-1.0 to 50-300 in 10.1-80.2 weight portions, soybean lecithin 88-440 weight portions, the mixture of cholesterol and soyasterol in the weight ratio of 9 to 1 in 40-200 weight portions, the mixture of polyglycol-4000 and polyglycol-2000 in the same ratio in 15-40 weight portions, sodium glucuronate in 100-280 weight portions, vitamin C in 160-800 and glutathione in 5-10 weight portions. The nanometer antiviral liposome medicine is used as the broad spectrum antiviral medicine.

The invention discloses a preparation technology of glucuronolactone, and belongs to the field of medicine raw material production. According to the preparation technology, acid pickling and water washing are mainly carried out on oxidized starch to remove impurities in the oxidized starch, the liquification and saccharification of the oxidized starch are faciliated, glycuronic acid, glucose, disaccharide and trisaccharide are obtained after the saccharification of the oxidized starch; by virtue of the property that glycuronic acid is easy to dissolve in ethyl alcohol (alcohol), but the glucose, disaccharide and trisaccharide are insoluble in alcohol, the glycuronic acid is subjected to separation and purification, so that the fermentation and impurity-removal technology is eliminated, and the production period is shortened by 72 h. The technology is simple in operation, short in reaction time, and low in requirements for equipment; the glucuronolactone prepared by the technology is high in yield and high in purity.

A fluorescent probe for measurement of UDP-glucuronosyltransferase, which comprises a fluorescein derivative, wherein in the fluorescein derivative, the 2-carboxy group on the benzene ring of fluorescein is replaced with another monovalent substituent, provided that said substituent is a substituent other than sulfo group, and the substituent does not have carboxy group or sulfo group, and wherein the fluorescein derivative may have an arbitrary substituent at a position on the benzene ring other than the 2-position, and the fluorescein derivative may have a substituent selected from the group consisting of an alkoxy group and a halogen atom at the 2-position and / or the 7-position of fluorescein.

The invention discloses a method for preparing a hyaluronan oligosaccharide chain modified flavonoid compound carrying glucuronic acid on the terminal, and belongs to the technical field of biological pharmacy. According to the method, a flavonoid compound carrying glucuronic acid on the terminal is selected as a start, and a difunctional hyaluronic synthase with beta(1->4) O-linked N-acetylgtucosamine activity and beta (1->3) glucuronyl transferase activity is utilized to synthesize a hyaluronan oligosaccharide chain based on glucuronic acid on the terminal, so that the hyaluronan oligosaccharide chain modified flavonoid compound is prepared. The method can be used for avoiding frequent protecting and de-protecting steps of chemical synthesis, has the advantages of economy, environmental friendliness, high efficiency and the like, is capable of enlarging derivation of flavonoid compounds, preparing novel flavonoid medicines with a drug delivery target label and opening a novel means for researches and development of novel target anti-cancer medicines, and has potential clinical application prospects.

The invention discloses a chrysoeriol-7-O-beta-D-ethyl glucuronate. The structural formula of the chrysoeriol-7-O-beta-D-ethyl glucuronate is A. The invention also discloses an extraction method of the chrysoeriol-7-O-beta-D-ethyl glucuronate and application of the chrysoeriol-7-O-beta-D-ethyl glucuronate to preparing antioxidant drugs, antioxidant cosmetics, hypoglycemic drugs and anti-tumor drugs.